AnaptysBio

locking horns fight battle lock horns
Favicon Fierce Pharma

GSK's Tesaro, AnaptysBio lock horns over Jemperli agreement

Some four years into Jemperli’s commercial run, a rift has emerged between GSK unit Tesaro and the cancer drug's original developer, AnaptysBio.
Fraiser Kansteiner Nov 21, 2025 9:46am
Golfer devastated after just barely missing a putt

AnaptysBio abandons rosnilimab for UC after phase 2 fail

Nov 10, 2025 10:05am
direction arrow

Anaptys plans to split into 2 businesses

Sep 30, 2025 9:35am
blocks stack target climb build arrow meet

AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2

Feb 12, 2025 9:57am
Person throwing piece of paper into full waste bin

Anaptys scraps atopic dermatitis asset after ph. 2 fail

Dec 11, 2024 11:02am
MA

Anaptys picks up rival to Biogen autoimmune asset from Centessa

Nov 28, 2023 6:30am